Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FDOPA PET-CT for Suspected Glioblastoma Recurrence
NCT02176720Phase 1Terminated
- Sponsor
- Houston Methodist Research Institute
- Start
- May 2014
- Primary completion
- Mar 2016
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of Fluorodopa F 18 in glioblastoma (GBM), sponsored by Houston Methodist Research Institute. Primary endpoint: Diagnostic accuracy compared to standard diagnostics without PET at 5 years. Started May 2014; status: terminated.
02
Drugs
Fluorodopa F 18
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT02176720.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02176720.